Rapport Therapeutics’ (RAPP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Rapport Therapeutics (NASDAQ:RAPP) in a report issued on Tuesday morning, MarketBeat.com reports. The brokerage currently has a $66.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. BTIG Research raised their target price on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Wednesday, September 23rd. Leerink Partners started coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price target on the stock. Guggenheim assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday, October 6th. They set a “buy” rating and a $65.00 price target on the stock. Finally, UBS Group started coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They set a “buy” rating and a $71.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Rapport Therapeutics has a consensus rating of “Buy” and a consensus target price of $68.36.

Rapport Therapeutics Trading Up 5.9%

RAPP stock opened at $26.53 on Tuesday. The company’s 50 day simple moving average is $39.44 and its 200-day simple moving average is $39.02. Rapport Therapeutics has a 12 month low of $23.75 and a 12 month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, analysts predict that Rapport Therapeutics will post -4.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Rapport Therapeutics news, Director Paul M. Silva acquired 3,680 shares of the company’s stock in a transaction dated Thursday, October 22nd. The stock was bought at an average price of $27.07 per share, with a total value of $99,617.60. Following the completion of the transaction, the director directly owned 3,680 shares of the company’s stock, valued at approximately $99,617.60. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven M. Paul purchased 35,714 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The shares were acquired at an average cost of $27.28 per share, with a total value of $974,277.92. Following the completion of the transaction, the director owned 77,380 shares in the company, valued at $2,110,926.40. This trade represents a 85.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 58,094 shares of company stock valued at $1,566,358 and have sold 97,976 shares valued at $4,420,349. 12.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. TRV GP V LLC acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at about $261,709,477. ARCH Venture Management LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth approximately $155,376,512. BlackRock Inc. acquired a new position in Rapport Therapeutics during the 2nd quarter worth approximately $112,500,000. Johnson & Johnson purchased a new position in Rapport Therapeutics in the 2nd quarter worth approximately $74,360,823. Finally, TRV GP VI LLC purchased a new position in Rapport Therapeutics in the 2nd quarter worth approximately $40,387,314.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.